Alzheimer's Foundation of America
Select text size: a | a | a
 

Alzheimer's Disease Clinical Trials

Find a Trial

To find a trial, please view the list below. Also visit www.clinicaltrials.gov.

Search by State:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ALABAMA

 

Back to Top

ALASKA

 

Back to Top

ARIZONA

Location: Gilbert
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Phoenix
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Sun City
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

ARKANSAS
CALIFORNIA

Location: Encino
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Long Beach
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease

The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due Alzheimer’s Disease (AD) or mild AD who test positive for amyloid plaque.

Enrollment Status: Recruiting

Study Dates: Start: March 2012 Expected Completion: February 2014

Condition: Alzheimer's disease
Age Eligibility: 55 years or older
Gender Eligibility: Male or Female
Enrollment Goal: 129
Clinical Identifier: NCT01561430
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD)

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: March 2013 Expected Completion: January 2015

Condition: Alzheimer's disease
Age Eligibility: 66-90
Gender Eligibility: Male or Female
Enrollment Goal: 480
Clinical Identifier: NCT01741194
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Accera, Inc.

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: July 2015

Condition: Alzheimer's disease
Age Eligibility: 18-89
Gender Eligibility: Male or Female
Enrollment Goal: 500
Clinical Identifier: NCT01689233
Study Phase: Phase 3
Study Type: Interventional

Sponsor: TauRx Therapeutics Ltd

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Long Beach
CNS Network, Inc.

Trial Title and Description:
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH)

The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease (AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.

Enrollment Status: Recruiting

Study Dates: Start: November 2012 Expected Completion: January 2017

Condition: Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2/3
Study Type: Interventional

Sponsor: Merck

Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com

Back to Top

Location: Redding, CA

Trial Title and Description: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Enrollment Open

Study Dates: Oct 2013 to Jan 2017

Condition: Alzheimer's Disease, Dementia
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: Phase 3
Study Type: Intervention

Sponsor: Forum Pharmaceuticals

Contact Information:
Colleen Penny
Northern California Clinical Research Center
530-247-7049

Back to Top

Location: Sherman Oaks
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Simi Valley
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Valley Village
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

COLORADO

 

Back to Top

CONNECTICUT

Location:  Institute for Neurodegenerative Disorders – New Haven, CT.

Trial Title and Description:A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Enrollment Status: Active

Study Dates:  Nov. 2012 (41 months)

Condition: Alzheimer disease or MCI
Age Eligibility
: 50-90
Gender Eligibility: male and female
Enrollment Goal: 800 subjects
Clinical Identifier
: BAN2401
Study Phase: Phase 2
Study Type: Investigational drug study

Sponsor: Eisai Inc.

Contact Information:
Barbara Fussell RN
800-401-6067
bfussell@indd.org

Back to Top

DISTRICT OF COLUMBIA

Location: Washington, DC
Georgetown University

Trial Title and Description: A Phase 2 multi-center, randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T-817MA in patients with mild to moderate Alzheimer's (NOBLE)

NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: March 2014 - March 2016
Condition: Alzheimer's Disease
Age Eligibility: 55-85
Gender Eligibility: Both
Enrollment Goal: 450
Clinical Identifier: NCT02079909
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Toyama Chemical Co., Ltd.

Contact Information:
Kelly Behan
(202) 687-0413

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (H8A-MC-LZAZ/ADC-040-A4)
The A4 study is investigating a new drug intervention that may reduce the impact of a protein known as "amyloid" or "beta amyloid" forming plaques in the brain. Scientists believe that the accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss.

Enrollment Status: Enrolling
Study Dates:
Condition: Normal thinking and memory abilities
Age Eligibility: 65-85
Gender Eligibility: Both
Enrollment Goal:
Clinical Identifier:  NCT02008357
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) versus Placebo (EXPEDITION 3)
EXPEDITION 3 – a clinical research study looking at an investigational drug for mild Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: July 2013-December 2016
Condition: Alzheimer's Disease
Age Eligibility: 55 Years to 90 Years
Gender Eligibility: Both
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Eli Lilly and Company

Contact Information:
Erica Christian
20-687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease (HarmonyAD)
The HarmonyAD clinical research study is being conducted to determine if an investigational drug given as a pill can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: November 2012-May 2015
Condition: Alzheimer's Disease
Age Eligibility: 50 Years to 95 Years
Gender Eligibility: Both
Enrollment Goal: 400
Clinical Identifier: NCT01735630
Study Phase: Phase 2
Study Type: Interventional

Sponsor: Elan Pharma International Limited

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Merck AD- A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease (EPOCH)
Currently available medications help manage symptoms but do not slow the course of Alzheimer's disease. Through ongoing clinical research, doctors seek to study new investigational medications that
may control symptoms and, may possibly, help with treatment. We are evaluating the effectiveness and safety of an oral investigational medication that may help slow the progression of mild to moderate
Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: November 2012 - April 2017
Condition: Alzheimer's Disease
Age Eligibility: 55 Years to 85 Years
Gender Eligibility: Both
Enrollment Goal:1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2 Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp.

Contact Information:
Erica Christian
(202) 687-8800

Back to Top

Location: Washington, DC
Georgetown University

Trial Title and Description: A Novel fMRI biomarker of asymptomatic Alzheimer's disease.

Enrollment Status: Enrolling
Study Dates: September 2014
Condition: Normal cognitive function, Mild Cognitive Impairment, or Alzheimer's Disease
Age Eligibility: 55 years to 85 years
Gender Eligibility: Both
Enrollment Goal: 100
Clinical Identifier: --
Study Phase: --
Study Type:

Sponsor: Alzheimer's Drug Discovery Foundation

Contact Information:
Wesley Horton
(202) 687-9078

Back to Top

FLORIDA

Location: Deerfield Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jose De La Gandara
877-379-3718

Back to Top

Location: Delray Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mark Brody
877-379-3718

Back to Top

Location: Delray Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mark Brody
877-379-3718

Back to Top

Location: Destin
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Elizabeth Roberson
877-379-3718

Back to Top

Location: Fort Myers
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location:   Florida
University of Florida – Brain Imaging Rehabilitation and Cognition Lab

Trial Title and Description:An fMRI Model of Naming in Alzheimer’s Disease
Do you or someone you know have Alzheimer’s disease?

Participants are needed for a research study to help us better understand language problems in Alzheimer’s disease. Participants must be right handed, native English language speakers, and able to undergo an MRI scan. Compensation will be provided for undergoing the MRI scan. If interested please call the University of Florida at (352 ) 273-5249.

Enrollment Status:   Recruiting

Study Dates: 

Condition:  
Age Eligibility:  
Gender Eligibility:  
Enrollment Goal:  
Clinical Identifier:  
Study Phase: 
Study Type: 

Sponsor: 

Contact Information: 
BIRC Lab
(352) 273-5249

Back to Top

Location: Hallandadle Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Beth Safirstein
877-379-3718

Back to Top

Location: Hialeah
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Hialeah
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Miguel Flores
877-379-3718

Back to Top

Location: Hollywood
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Jacksonville
Baptist Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Sally Coxwell
904-202-7073
sallybrci@aol.com

Back to Top

Location: Melbourne
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Thomas Hoffman
877-379-3718

Back to Top

Location: Miami
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mario Cuervo
877-379-3718

Back to Top

Location: Miami
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Miami Beach
Wien Center for Clinical Research

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Peggy Roberts
305-674-2424
proberts@msmc.com
For more information, visit www.gapstudy.com

Back to Top

Location: Miami Beach
Wien Center, Mount Sinai Medical Center

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Peggy Roberts
305-674-2424
proberts@msmc.com

Ranjan Duara

Back to Top

Location: Miami Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Ranjan Duara
877-379-3718

Back to Top

Location: Naples
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Naples

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Anchor Research Center
Candy Pewanick
239-643-8805
www.KiokuStudy.com

Back to Top

Location: North Palm Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Walter Martinez
877-379-3718

Back to Top

Location: Ocala
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Ormond Beach
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Palm Beach Gardens
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Plantation
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard McLean
877-379-3718

Back to Top

Location: Sarasota
Roskamp Institute Memory Clinic

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Cheryl Rindfleisch
941-256-8018, ext 356
crindfleisch@rfdn.org
For more information, visit www.gapstudy.com

Back to Top

 

Location: Sarasota
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Roland Aung-din
877-379-3718

Back to Top

Location: Sunrise
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard Singer
877-379-3718

Back to Top


Location: Sunrise

Trial Title and Description: Efficacy and Safety of MK-7622 as Adjunct Therapy to Donepezil in Participants With Alzheimer's Disease (MK-7622-012)

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: August 2017
Condition: Mild to Moderate Alzheimer's disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 830
Clinical Identifier: NCT01852110
Study Phase: II
Study Type: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Sponsor: Merck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Mild-Moderate Alzheimer's Disease Treated With Donepezil

Enrollment Status: Enrolling
Study Dates: Start: January 2014 End: January 2016
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 50 years and older
Gender Eligibility: Male/Female
Enrollment Goal: 840
Clinical Identifier: NCT02006641
Study Phase: III
Study Type: Interventional
Sponsor: Lundbeck
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 13

Back to Top


Location: Sunrise

Trial Title and Description: A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

Enrollment Status: Enrolling
Study Dates: Start: October 2013 End: January 2017
Condition: Mild to Moderate Alzheimer's Disease
Age Eligibility: 55-85 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 790
Clinical Identifier: NCT01969136
Study Phase: III
Study Type: Interventional Allocation: Randomized
Sponsor: EnVivo
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.

Enrollment Status: Enrolling
Study Dates: Start: June 2012 End: September 2014
Condition: Mild to Moderate Alzheimer's disease with agitation
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 200
Clinical Identifier: NCT01584440
Study Phase: II
Study Type: Interventional
Sponsor: Avanir
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: November 2012 End: December 2013
Condition: Mild to Moderate Alzheimer's with agitation
Age Eligibility: 50-88 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 400
Clinical Identifier: NCT01735630
Study Phase: II
Study Type: Interventional
Sponsor: Elan
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Enrollment Status: Enrolling
Study Dates: Start: December 2012 End: December 2016
Condition: Mild Cognitive Impairment/Early Alzheimer's disease
Age Eligibility: 50-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 800
Clinical Identifier: NCT01767311
Study Phase: II
Study Type: Interventional
Sponsor: Eisai
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top


Location: Sunrise

Trial Title and Description: Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
Enrollment Status: Enrolling
Study Dates: Start: July 2013 End: December 2016
Condition: Mild Alzheimer's disease
Age Eligibility: 55-90 years of age
Gender Eligibility: Male/Female
Enrollment Goal: 2100
Clinical Identifier: NCT01900665
Study Phase: III
Study Type: Interventional
Sponsor: Eli Lilly
Contact Information: Neurology Clinical Research, Inc.
954-475-8171 ext. 138

Back to Top

Location: Tampa
The APECS Study

Trial Title and Description:
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD).

This study is evaluating an oral investigational medication that may help slow down the progression of what could be very early Alzheimer’s disease

Enrollment Status: Recruiting
Study Dates: Start: November 2013
Expected Completion: March 2018

Condition: Prodromal Alzheimer's disease
Age Eligibility: 50-85 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 1,500
Clinical Identifier: NCT01953601
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Contact Information:
844-603-0303
www.ApecsStudy.com

Back to Top

Location: Tampa
University of South Florida, Tampa / Suncoast

Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease

The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.

Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional

Sponsor: Baxter Healthcare Corporation

Contact Information:
Barbara Luhn
813-974-4355
bluhn@health.usf.edu

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top


For more information, connect with the Alzheimer’s Foundation of America’s licensed social workers. Click here or call 866.232.8484. Real People. Real Care.